SCHEMBL2014081

SCHEMBL2014081

Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1S

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
NT5E P21589 1/20 0.62
HIF1A Q16665 1/20 0.62
ADORA2A P29274 4/20 0.62
ADORA3 P0DMS8 4/20 0.62
ADORA2B P29275 3/20 0.61
CYP2C19 P33261 1/20 0.60
HPGD P15428 1/20 0.60
ADORA1 P30542 2/20 0.60
SLC29A1 Q99808 2/20 0.60
DPP4 P27487 1/20 0.60
MEN1 O00255 1/20 0.60
SLC28A1 O00337 1/20 0.60
MAP3K7 O43318 1/20 0.60
SLC28A2 O43868 1/20 0.60
GAPDH P04406 1/20 0.60
MAPK1 P28482 1/20 0.60
STAT6 P42226 1/20 0.60
PI4KA P42356 1/20 0.60
KMT2A Q03164 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL899617 1.00 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
Uridine SCHEMBL7700216 0.89 SLC29A1 (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL3970946 0.89 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL16555404 0.89 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL5033515 0.89 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL6663083 0.89 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL2424283 0.88 LMNA (0.64) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL62505 0.88 CYP2C19 (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL11481461 0.88 LMNA (0.61) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL14931005 0.88 CYP2C19 (0.62) LMNANT5EHIF1AADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3359670-B2 METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS MODERNATX INC (US) 2024-02-14 EP claimed
EP-3359670-B1 METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS MODERNATX INC (US) 2020-05-13 EP claimed
WO-2002062924-A1 INSTANT DEGRADATION OF PLASTICS TO SOLUBLE NON-TOXIC PRODUCTS ROSEN OREN (IL) 2002-08-15 WO claimed
US-20020004590-A1 Method for producing nucleoside-5'-phosphate ester MIHARA YASUHIRO (JP) 2002-01-10 US claimed
US-5420105-A Drug delivery to targeted cells ALETHEON PHARMACEUTICALS, INC. 1995-05-30 US claimed
WO-2024133160-A1 HEPATITIS B COMPOSITIONS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-06-27 WO disclosed
EP-4387596-A1 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME GlaxoSmithKline Biologicals SA (BE) 2024-06-26 EP disclosed
EP-4387597-A1 FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF GlaxoSmithKline Biologicals SA (BE) 2024-06-26 EP disclosed
CN-114206463-B Lipid compounds and lipid nanoparticle compositions 苏州艾博生物科技有限公司 2024-06-11 CN disclosed
US-11993777-B2 Compositions and methods for treating non-age-associated hearing impairment in a human subject AKOUOS, INC. (US) 2024-05-28 US disclosed
CN-118043306-A Lipid compounds and lipid nanoparticle compositions 苏州艾博生物科技有限公司 2024-05-14 CN disclosed
WO-2024097875-A1 FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS SHATTUCK LABS, INC. (US) 2024-05-10 WO disclosed
US-6355472-B2 ACID PHOSPHATASE AJINOMOTO CO., INC. (JP) 2002-03-12 US disclosed
US-20020004590-A1 Method for producing nucleoside-5'-phosphate ester MIHARA YASUHIRO (JP) 2002-01-10 US disclosed
EP-1170370-A2 Method for producing nucleotide by fermentation Ajinomoto Co., Inc. (JP) 2002-01-09 EP disclosed
US-6207435-B1 MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES AJINOMOTO CO., INC. (JP) 2001-03-27 US disclosed
US-6015697-A ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY AJINOMOTO CO., INC. (JP) 2000-01-18 US disclosed
US-6010851-A ALLOWING AN ACID PHOSPHATASE HAVING A LOWERED PHOSPHOMONOESTERASE ACTIVITY TO ACT UNDER A CONDITION OF PH 3.0 TO 5.5 ON A NUCLEOSIDE AND A PHOSPHATE GROUP DONOR AJINOMOTO CO., INC. (JP) 2000-01-04 US disclosed
EP-0857788-A2 Method for producing nucleoside-5'-phosphate ester Ajinomoto Co., Inc. (JP) 1998-08-12 EP disclosed
EP-0832970-A1 PROCESS FOR PRODUCING NUCLEOSIDE-5'-PHOSPHATE Ajinomoto Co., Inc. (JP) 1998-04-01 EP disclosed